Form 8-K BIOGEN INC. For: Oct 20

Go back to Form 8-K BIOGEN INC. For: Oct 20

Biogen (BIIB) PT Lowered to $390 at Oppenheimer

October 20, 2021 6:05 PM EDT

Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $450.00) while maintaining an Outperform rating.

The analyst commented, "Bolstered by a 3Q top- and bottom-line beat, BIIB outlined a number of steps to support the Aduhelm launch but deferred... More